Phase II Intranasal Insulin Study
This investigation studies the effect of insulin on cognition and function in individuals with amnestic mild cognitive Impairment (aMCI) or mild Alzheimer’s disease (AD) when delivered as a nasal spray (intranasally).
Study Length: 8 months
Lundbeck Study (STARBEAM) – Recruitment closed
This investigation studies a medication (Lu AE58054) that is expected to work in conjunction with Aricept for symptomatic treatment in mild-moderate Alzheimer's disease. There is also an option to participate in a 32 week extension study.
Study Length: 28 weeks and an additional 32 weeks
Merck MK-831 019 Study – Recruitment closed
This is a study in mild cognitive impairment testing a novel drug (MK-8931) that is expected to reduce levels of Abeta, an abnormal protein that is associated with Alzheimer’s disease. Mild cognitive impairment is considered an earlier stage of memory loss that may progress to dementia. The decision to study this drug in the mild cognitive impairment population is based on the hypothesis that treating this disease earlier in the process may lead to better outcomes.
Study Length: 112 weeks
Pilot Down syndrome Study
This study investigates the effect of insulin on the memory and cognitive function in individuals with Down syndrome when delivered as a nasal spray (intranasally).
Study Length: 6 weeks
This is a study to assess the impact of amyloid PET imaging on patient outcomes compared to standard of care alone. The results of this study will be used to help assess whether the Centers for Medicare and Medicaid Services (CMS) will cover the cost of this type of imaging in the future. This study does not use an intervention.
Study Length: 3 visits over approximately 3 months, CMS claims about your care may be used for up to 3 years
HealthPartners Center for Memory & Aging
640 Jackson St. St. Paul, MN 55101